Psoriasis is an immune-mediated inflammatory disease. It is officially classified this way by both the American Academy of Dermatology and the National Psoriasis Foundation, and the inflammation it causes extends well beyond the skin. What looks like a surface-level skin problem is actually driven by an overactive immune system that sends inflammatory signals throughout the body, raising the risk of heart disease, diabetes, and joint damage.
What Makes Psoriasis Inflammatory
In healthy skin, cells mature and shed over about 50 days. In psoriatic skin, that cycle compresses to roughly 5 days. This dramatic acceleration is not a skin defect. It is caused by immune cells flooding the skin with inflammatory signaling proteins that force skin cells to multiply far faster than normal, producing the thick, raised plaques psoriasis is known for.
The central pathway involves two key signaling proteins working in sequence. The first, IL-23, is produced by immune cells in the skin and acts as an upstream regulator. It keeps a population of immune cells called TH17 cells active and multiplying. Those TH17 cells then release a second protein, IL-17, which acts directly on skin cells. IL-17 triggers skin cells to proliferate rapidly and to release even more inflammatory signals, including a third protein called TNF. This creates a self-reinforcing loop: inflammation drives skin cell growth, which triggers more inflammation.
A third protein, TNF, amplifies the process further. Together, IL-23, IL-17, and TNF form the core of the inflammatory cascade in psoriasis. Levels of IL-23 are significantly elevated in psoriatic skin compared to unaffected skin on the same person, confirming that these aren’t normal background signals but a localized inflammatory overdrive.
Genetics and Inflammatory Susceptibility
Not everyone develops psoriasis, and genetics play a significant role in who does. The gene most strongly linked to psoriasis susceptibility is called HLA-Cw6, which sits within a region of the genome involved in immune function. Depending on the population studied, anywhere from 10% to 77% of people with psoriasis carry this gene variant. People who carry it tend to develop psoriasis earlier in life and experience more severe disease.
HLA-Cw6 appears to work by influencing how the immune system recognizes the body’s own tissues. It helps present fragments of the body’s own proteins to immune cells, potentially triggering them to mount an inflammatory attack against healthy skin. This connects the genetic predisposition directly to the inflammatory nature of the disease: the gene doesn’t cause bad skin, it causes an immune system primed to overreact.
What Triggers Inflammatory Flares
People with psoriasis often notice that new plaques appear at sites of skin injury, a well-documented response called the Koebner phenomenon. Cuts, burns, tattoos, surgical incisions, and even radiation exposure can all trigger new lesions. The mechanism involves mast cells at the injury site releasing inflammatory mediators, including IL-17 and IL-6, the same proteins involved in the core inflammatory cascade. Essentially, normal wound-healing signals get hijacked by the overactive psoriatic immune system and converted into full-blown plaques.
Other common triggers include infections (particularly strep throat), psychological stress, and certain medications. Each of these activates the immune system in ways that, in a person genetically predisposed to psoriasis, can tip the balance toward an inflammatory flare.
Inflammation Beyond the Skin
One of the most important things to understand about psoriasis is that the inflammation is not confined to the skin. Blood markers of systemic inflammation are measurably elevated. C-reactive protein (CRP), a standard marker of inflammation in the body, is elevated above 5 mg/L in 52% of people with psoriasis compared to just 14% of people without it. CRP levels also track with disease severity: people with more extensive skin involvement have higher levels, and those who also have metabolic syndrome show even greater elevations.
This systemic inflammation has real consequences. Psoriasis is associated with a significantly higher risk of cardiovascular disease, and heart-related conditions represent the single largest contributor to excess mortality in people with psoriasis. The connection follows a concept researchers call the “psoriatic march”: chronic inflammation from psoriasis promotes insulin resistance and damages blood vessel walls, which accelerates the buildup of arterial plaque. Over time, this increases the risk of heart attack and stroke, independent of other cardiovascular risk factors like smoking or high cholesterol.
Beyond heart disease, psoriasis is linked to obesity, type 2 diabetes, high blood pressure, abnormal cholesterol levels, metabolic syndrome, kidney disease, and mood disorders including depression. These are not coincidental. They share inflammatory pathways with psoriasis, and the systemic inflammation psoriasis generates actively contributes to their development.
Psoriatic Arthritis
About 20% of people with psoriasis develop psoriatic arthritis, a condition where the same inflammatory process attacks the joints. Among those with moderate to severe skin disease, the rate rises to roughly 25%. Estimates across studies range from 4% to 31%, partly because many cases go undiagnosed for years. Psoriatic arthritis causes joint pain, stiffness, and swelling that can lead to permanent joint damage if the inflammation is not controlled. In most cases, skin symptoms appear years before joint symptoms, giving a window for early monitoring.
How Treatments Target Inflammation
Modern psoriasis treatments work precisely because psoriasis is an inflammatory disease. Rather than simply slowing skin cell growth, the most effective therapies interrupt the inflammatory cascade at specific points.
Biologic therapies are engineered proteins that block individual inflammatory signals. TNF inhibitors were the first generation, neutralizing the TNF protein that amplifies inflammation. IL-17 inhibitors block the downstream effector signal that directly drives skin cell overproduction, often producing rapid skin clearance. The newest class, IL-23 inhibitors, targets the upstream regulator that keeps the entire TH17 cell population activated. By cutting off the signal at its source, IL-23 inhibitors can produce lasting remission with less frequent dosing.
The fact that blocking a single inflammatory protein can clear psoriasis almost entirely is itself powerful evidence of the disease’s inflammatory nature. These treatments also tend to improve associated conditions: people on biologic therapy often see improvements in joint symptoms, cardiovascular markers, and metabolic health, reinforcing that the same inflammatory process drives damage across multiple organ systems.